HARROW, INC. 10-K

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES Market Information for Common Stock Our common stock is listed on The Nasdaq Stock Market LLC under the symbol “HROW”. Performance Graph Our common stock is traded on The Nasdaq Stock Market LLC and is a component of both the Nasdaq Composite Index and the Nasdaq Biotechnology Index. The following graph shows cumulative total stockholder return (i.e., price change plus reinvestment of dividends) on our common stock over the period commencing December 31, 2020 and ending on December 31, 2025, to that of the total return for the Nasdaq Composite Index and the Nasdaq Biotechnology Index, assuming an investment of $100 on December 31, 2020. The stock performance shown on the graph represents historical stock performance and is not necessarily indicative of future stock price performance COMPARISON OF 5 YEAR CUMULATIVE TOTAL RETURN* Among Harrow Inc., the NASDAQ Composite Index and the NASDAQ Biotechnology Index *$100 Invested on 12/31/2020 in stock or index, including reinvestment of dividends. Fiscal year ending December 31. The graph and related information is furnished under this Part II, Item 5 of this Annual Report on Form 10-K and shall not be deemed “soliciting material” or be “filed” with the SEC and shall not be incorporated by reference into any filing we make under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation by reference language in such filing. Holders As of February 25, 2026, there were approximately 56 stockholders of record (excluding an indeterminable number of stockholders whose shares are held in street or “nominee” name) of our common stock. Dividends We have not paid any dividends on our common stock since our inception and do not expect to pay dividends on our common stock in the foreseeable future. Securities Authorized for Issuance under Equity Compensation Plans The information required by this item will be set forth in the definitive proxy statement we will file in connection with our 2026 Annual Meeting of Stockholders and is incorporated by reference herein. 50 Issuer Purchases of Equity Securities During the three months ended December 31, 2025, the Company withheld shares of common stock to satisfy employee minimum statutory tax withholding obligations payable upon the vesting of restricted stock, as follows: Period Total Number of Shares Purchased (a) Weighted Average Price Paid per Share Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (b) Maximum Number of Shares That May Yet Be Purchased Under the Plans or Programs (b) October1 – October 31 631 39.36 - - November 1 – November 30 73 37.77 - - December 1 – December 31 - $ - - - Total 704 $ 39.20 - - (a) Represents shares withheld to satisfy the payment of tax obligations related to the vesting of restricted stock awards. (b) We had no publicly announced repurchase programs for shares of our common stock during the year ended December 31, 2025. Recent Sales of Unregistered Securities None. ITEM 6. [RESERVED]